Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 382 of 6351
-
New study aims to slash cervical cancer deaths in HIV-positive women
Knowledge-focused Not yet recruitingBackground In sub-Saharan Africa (SSA), human papillomavirus (HPV) and HIV create a dual burden of disease that causes significant morbidity and mortality in the form of cervical cancer (CC). Women living with HIV (WLWH) have a six-fold higher risk of developing precancerous lesi…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to shrink sinus tumors before surgery
Disease control Not yet recruitingThe main objective of this prospective study is to evaluate the effectiveness and safety of a novel neoadjuvant therapy for patients with locally advanced sinonasal carcinoma (SNC). The treatment consists of the standard TP chemotherapy regimen (docetaxel and cisplatin) combined …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental antibodies aim to block cat allergy eye itch
Symptom relief Recruiting nowThis study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat". These medicines are also known as the "study drugs". The aim of the study…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat stomach cancers
Disease control Not yet recruitingThis is a phase 2 multicenter study that will evaluate the safety and efficacy of sacituzumab tirumotecan (Sac-TMT) plus fruquintinib for the treatment of participants with locally advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma who have faile…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could Two-Drug cocktails tame stubborn inflammatory bowel disease?
Disease control Recruiting nowCrohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Magnetic heat zaps infection in knee implants without removal
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether the Sola2 AMF Knee System, when added to surgery and antibiotic treatment, can safely improve outcomes, knee function, and quality of life in adults with knee implant infection. The main questions this study aims to answer are:…
Sponsor: Solenic Medical, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can a biologic drug calm the gut in ulcerative colitis? a Real-World trial seeks answers
Disease control Recruiting nowIn a real-world setting, this study systematically evaluates the clinical efficacy and safety of guselkumab (GUS) in the treatment of ulcerative colitis (UC), encompassing multi-dimensional outcomes including clinical remission, biochemical remission, endoscopic remission, histol…
Sponsor: Second Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can ancient qigong movements fortify pelvic health after childbirth?
Prevention Not yet recruitingThe goal of this clinical trial is to determine whether a prenatal exercise program integrating Liuzijue qigong with traditional levator ani training, guided by the MoVo (Motivation-Volition) theory and delivered via a supervised mobile application, can effectively prevent postpa…
Sponsor: Yu xin Qian • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
New drug targets two cancer proteins in advanced tumors
Disease control Recruiting nowThis is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by c…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Could a new drug help keep myasthenia gravis symptoms at bay?
Disease control Recruiting nowThe primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.
Phase 2 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can targeted chemo infusion outperform pills in biliary tract cancer?
Disease control Not yet recruiting3\. Study Design 3.1.1 Study Site and Overall Population Overview This study is a prospective, open-label, randomized controlled clinical trial designed to observe and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy compared with capecitabine in the adj…
Phase 4 • Sponsor: Zhai Wenlong • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Targeting the immune system: a new antibody may free Graves' patients from daily drugs
Disease control Recruiting nowIn this study, researchers will learn more about the use of felzartamab in participants with Graves' Disease, also known as GD. GD is an autoimmune disease, which means the body's immune system attacks its own healthy cells. In people with GD, the immune system produces abnormal …
Phase 2 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can combined Arm-Leg training rebuild balance after stroke?
Disease control Recruiting nowStrokes frequently affect motor function, balance, and coordination, reducing independence. HABIT-ILE combines upper and lower limb exercises to improve coordination and balance. Objective To determine the effectiveness of HABIT-ILE on balance and coordination among stroke patie…
Sponsor: Riphah International University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New device could ease lung pressure in heart failure patients
Disease control Recruiting nowThe goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associ…
Sponsor: Pulnovo Medical, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Blood test may spare lung cancer patients from chemo
Disease control Not yet recruitingAnti-PD-1 monotherapy has demonstrated significant clinical efficacy in advanced or metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (tumor proportion score \[TPS\] \>50%), outperforming platinum-based chemotherapy in terms of objective response rate (ORR)…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug combo aims to shrink skin cancer before surgery
Disease control Not yet recruitingThe NEOPECS trial is a phase II prospective, single-arm, non-randomised interventional trial for patients with borderline resectable locally advanced cutaneous squamous cell carcinoma with a 6-participant safety lead in to ensure safety of the combination in the neoadjuvant setti…
Phase 2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug cocktail takes on rare skin cancer
Disease control Not yet recruitingVG712 (A-dmDT390-bisFv(UCHT1) fusion protein) is a recombinant anti-CD3 immunotoxin that selectively depletes CD3-positive T cells through irreversible inhibition of protein synthesis. This Phase II study (CurbMF-001) evaluates the safety and efficacy of VG712 compared with mogam…
Phase 2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
In-Body CAR-T: a new shot at fighting blood cancers?
Disease control Not yet recruitingThis study is a single-arm, open-label clinical investigation to evaluate the tolerance, safety and preliminary efficacy of CAR-T (U96) in the treatment of relapsed/refractory B-cell tumors. The study will be conducted in two disease types, acute B-lymphoblastic leukemia and B-ce…
Phase 1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug trial aims to ease muscle weakness in rare disease
Disease control Not yet recruitingThe primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo shows promise for tough lung cancer
Disease control Not yet recruitingThis is a multicenter, open-label, randomized controlled phase II/III study evaluating the efficacy and safety of QL1706 in combination with anlotinib as later-line treatment in patients with advanced lung cancer.
Phase 2/3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC